[Comunicado de imprensa – ainda não publicado] Merck anuncia que o antiviral oral Molnupiravir reduziu o risco de internação ou morte em cerca de 50%, comparado ao placebo, em pacientes com COVID-19 leve ou moderada.

Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study

Comentários:

Expert reaction to interim analysis of oral antiviral molnupiravir – Science Media Centre

Merck’s antiviral pill reduces hospitalization of Covid patients, a possible game-changer for treatment – STAT

Covid antiviral pill can halve risk of hospitalization – BBC

Why Merck’s Covid-19 pill molnupiravir could be so important – Vox

‘Unquestionably a game changer!’ Antiviral pill cuts COVID-19 hospitalization risk – Researchers excited about Merck drug, but caution data are preliminary and price is high – Science

Comentários no Twitter

.@DrEricDing convinced many that stopping the #molnupiravir trial early for benefit was a good idea

But it was NOT

Large body of evidence suggests that stopping early for benefit biases the results: overestimates the benefits of the treatment #EBM https://t.co/b3tHEtliO0 https://t.co/LwuCgqcY0C pic.twitter.com/vyPWc0nd37

— Kari Tikkinen (@KariTikkinen) October 2, 2021

(fio – clique para saber mais)

💡BREAKING—New oral anti-viral drug *molnupiravir* cuts risk of #COVID19 hospitalization and death **in HALF** in a randomized trial. Results so astounding that the trial is being stopped early, and Merck plans to apply for emergency authorization ASAP. 🧵 https://t.co/g8JGNzvuRg pic.twitter.com/K1SwC3QFXS

— Eric Feigl-Ding (@DrEricDing) October 1, 2021